Supplementary figures

Supplementary figure 1. Kaplan-Meier curves for time to treatment discontinuation (upper left), time to dose reduction (upper right), progression-free survival (bottom left), and overall survival (bottom right).

Legend for supplementary figure 1: QOL, quality of life.

Supplementary figure 2. Swimmer plot describing the time lag between worsening physical functioning and treatment discontinuation.

Legend for supplementary figure 2: PF, physical functioning.
**Supplementary Material**: Dose reduction criteria

**Taxane group**

1) Pyrogenic neutropenia of Grade $\geq 3$

2) Platelet count of $\leq 50,000/\text{mm}^3$ and subcutaneous hemorrhage

3) Platelet count of $\leq 25,000/\text{mm}^3$

4) Platelet count of $<100,000/\text{mm}^3$ on day prior to or day of course commencement

5) Grade 3 severity of any of the following non-hematological toxicities: weight decrease, weight gain, diarrhea, nausea/vomiting, neuropathy-motor, neuropathy-cognitive, joint pain, myalgia, and fatigue.

**Anthracycline group**

1) Febrile neutropenia of Grade $\geq 3$

2) Platelet count $\leq 50,000 / \text{mm}^3$ and subcutaneous hemorrhage

3) Platelet count $\leq 25,000 / \text{mm}^3$

4) Platelet count on the day of administration or on the day before $< 100,000 / \text{mm}^3$

5) Any of the following non-hematological Grade 3 toxicities: weight loss, weight gain, diarrhea, nausea and vomiting, and fatigue

**S-1 group (SELECT BC study)**

(1) Grade $\geq 4$ hematological toxicities (neutrophils, hemoglobin, and platelets)

(2) Grade $\geq 3$ of any of the following non-hematological toxicities:

Non-hematological toxicities: adverse events outside the CTCAE v3.0 “blood/bone-marrow” classification

**S-1 group (SELECT BC CONFIRM study)**

(1) Grade $\geq 3$ of any hematological toxicities (neutrophils, hemoglobin, platelets).

(2) Grade $\geq 3$ of any of the following non-hematological toxicities:
Non-hematological toxicities: adverse events outside the CTCAE v3.0 “blood/bone-marrow” classification